ac-immune-logo-rgb.png
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
May 17, 2021 07:00 ET | AC Immune SA
Previous interim results showing strong safety and potent immunogenicity support trial expansion and advancement of ACI-35.030 into Phase 2b/3 Alternative vaccine candidate also advances to...
ac-immune-logo-rgb.png
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
April 28, 2021 07:00 ET | AC Immune SA
Reported potent interim immunogenicity results for anti-pTau Alzheimer’s vaccine in ongoing Phase 1b/2a study, which support further development into Phase 2/3Initiated first-in-human clinical study...
ac-immune-logo-rgb.png
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
March 31, 2021 16:30 ET | AC Immune SA
Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investments for several clinical-stage companies as a Partner at Sofinnova Investments LAUSANNE,...
ac-immune-logo-rgb.png
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease
March 31, 2021 07:00 ET | AC Immune SA
LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will...
ac-immune-logo-rgb.png
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline
March 26, 2021 07:00 ET | AC Immune SA
Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases Webinar will take place on Wednesday, March 31, 2020 at 10:00 AM ET ...
ac-immune-logo-rgb.png
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
March 23, 2021 07:00 ET | AC Immune SA
Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3 Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b...
ac-immune-logo-rgb.png
AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine
March 16, 2021 07:00 ET | AC Immune SA
Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium Reported new data in non-human primates for optimized vaccine formulation which shows...
ac-immune-logo-rgb.png
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases
March 09, 2021 07:00 ET | AC Immune SA
Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43 First biologically active...
ac-immune-logo-rgb.png
AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference
February 24, 2021 07:00 ET | AC Immune SA
LAUSANNE, Switzerland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
ac-immune-logo-rgb.png
AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference
February 17, 2021 07:00 ET | AC Immune SA
LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...